Adjunctive use of xanomeline/trospium chloride (Cobenfy) offered no statistically significant benefit over placebo in adults with symptoms of schizophrenia inadequately controlled by an atypical ...

Personalized treatment approaches are crucial for older, frail, and high-risk multiple myeloma patients, focusing on dosing intensity rather than the number of drugs. The MAIA study showed ...

Cobenfy's recent trial failure and underperformance of key assets like Sotyktu and Abecma contribute to a cautious outlook, prompting a rating downgrade to "Hold." Despite debt and market ...

Growth Portfolio revenues reached $5.6 billion, up 16% on a reported basis (18% Ex-FX), primarily driven by Opdivo, Breyanzi, Reblozyl, and Camzyos and reflected the strong early U.S. launch of ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is serving up mixed results for the first three months of the year.

It also comes just days after Bristol Myers' recently approved schizophrenia drug, Cobenfy, disappointed in a large clinical trial, leading some Wall Street analysts to substantially lower their ...

The company also noted strong early U.S. launch results for Cobenfy. Conversely, the Legacy Portfolio revenues declined 20% to $5.6 billion, primarily due to generic competition for drugs like ...

Cobenfy Phase 3 Arise results didn’t reach its end point. BMY down 5% after hours. I’m hoping this won’t read through to Puretech given Cobenfy future royalties haven’t factored favourably ...

The prescribed dosage for cephalexin may depend on a person’s individual treatment plan. Other factors, including your specific diagnosis, medical history, and body weight, may affect your ...

We chat about the recent bounceback in biotech stocks, disappointing results from Bristol Myers Squibb’s schizophrenia drug Cobenfy, new allegations about entrepreneur Sam Waksal, and more.

Over the period from the first dosing in August 2020 to the last dosing in September 2022, clinicians accepted 97.2% of the recommended doses, with some patients receiving optimal doses that were ...